 |
 |
 |
 |
 |
 |
 |
 |
 |
|
     |
|||||||||
 |
|||||||||
Avontec's decoy oligonucleotides provide a novel anti-inflammatory mode of action - immune normalization - with the following advantages:
- New mode of action with potential for better safety and potency
- Lower price
- Improved compliance
- Different from all other biologics-based therapies
- Different from all other small molecule approaches
- Suitable for coordinated administration with biologics
Additional clinical studies are in preparation not only to extend the application within a certain therapeutic area but also to expand use into new indications such as rheumatoid arthritis and inflammatory bowel disease (current status: preclinical).
 |
 |
 |
 |
 |